Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T Prostate Cancer and Prostatic Diseases advance online publication, June 24 2014. doi:10.1038/pcan.2014.21 Authors: E J Small, C S Higano, P W Kantoff, J B Whitmore, M W Frohlich &D P Petrylak
Source: Prostate Cancer and Prostatic Diseases - Category: Urology & Nephrology Authors: Source Type: research

Related Links:

This study included 74 Japanese patients with CRPC who were treated with cabazitaxel between 2014 and 2017. Associations between clinicopathological factors including serum markers and progression-free survival (PFS) and overall survival (OS) were investigated. On multivariate analysis, high Gleason score [≥9 vs. ≤7; hazard ratio (HR), 95% confidence interval (CI): 2.00 (1.01–4.34); P = 0.047], presence of pain [HR, 95% CI: 2.02 (1.14–3.58); P = 0.016], and lactate dehydrogenase (LDH) level [HR, 95% CI: 47.31 (3.79–577.49); P = 0.0019] were significantly associated with PFS. Similarly, number of doc...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Clinical Reports Source Type: research
Bone is one of the most common sites of metastases, particularly for breast, lung, prostate cancer, and multiple myeloma [1]. The most typical anatomical regions of bone metastases are the spine, the proximal femur, and the humerus [2]. Particularly for proximal femur lesions, 50% occur in the femoral neck, 30% occur in the subtrochanteric region, and 20% occur in the intertrochanteric region [3]. While current advances in oncology have improved the mean overall survival of patients with metastatic musculoskeletal disease, bone metastases cause significant morbidity, including pain, limitations in daily activities, and pat...
Source: Injury - Category: Orthopaedics Authors: Source Type: research
ConclusionDT revealed the best correlation to validated structured questionnaires of diverse dimensions with clear potential for quick screening of patients with psychological suffering and in need of further evaluation and support.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
Madam — Historically, effective systemic treatments for men diagnosed with advanced or metastatic prostate cancer were limited. Most would experience an initial but temporary symptomatic and biochemical response to castration-based therapy with either bilateral orchidectomy or luteinising hormone-releas ing hormone agonists. At this stage, the addition of antiandrogens, steroids, stilboestrol or chemotherapy with mitoxantrone could be considered. These agents had short-lived benefits with no improvement in survival and limited symptomatic or palliative response for bone pain.
Source: Clinical Oncology - Category: Radiology Authors: Tags: Letter Source Type: research
In this study, we hypothesized that heme oxygenase-1 (HO-1), an enzyme responsible for degradation of heme to carbon monoxide (CO), bilirubin, and iron is an important regulator of inflammation and epithelial responses in the prostate. Injection of non-uropathogenic E. coli (MG1655 strain) or PBS into the urethra of mice led to increased numbers of CD45+ leukocytes and mitotic markers (phosphorylated histone H3 and phosphorylated extracellular signal-regulated kinase; Erk1/2) in the prostate glands. Leukocyte infiltration was elevated in prostates harvested from mice lacking HO-1 in the myeloid compartment. Conversely, exo...
Source: The American Journal of Pathology - Category: Pathology Authors: Tags: Am J Pathol Source Type: research
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Beyond its effects on the body, medical care can be a balm for the mind. Extensive treatment can feel like a promise that doctors have done everything possible. But that perceived security can come at a high price. As health costs soar, patients are emptying their pockets for care that may not make them healthier, research suggests. Last year, a 5,000-person trial showed that for patients with chronic but stable heart disease, surgical procedures such as stenting and bypass did not reduce the risk of heart attack or death more than lifestyle interventions and medication. Even patients with extensive damage did not, on aver...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Surgery Source Type: news
AbstractPurposeWe aimed to compare total orchiectomy, subcapsular orchiectomy, and luteinizing hormone-releasing hormone (LHRH) analogue treatment in patients with hormone-sensitive metastatic prostate cancer in terms of efficacy of androgen deprivation treatment (ADT), patient satisfaction, health-related quality of life (HRQoL), development of phantom testis syndrome (PTS), and post-traumatic stress disorder (PTSD).MethodAmong 272 patients treated between July 2015 and January 2019, 189 patients were enrolled in this prospective, cohort study and the patients were divided into three groups: group I, bilateral total orchi...
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
CONCLUSIONS This study was based on pharmacological networks results for the prediction of the multi-constituent, multi-target, and multi-pathway mechanisms of CKI, which might be a promising potential therapeutic and prevention candidate for anti-cancer. However, based on computer data mining and analysis, this study still needs to be further verified by in vivo/in vitro experiments, and the safety of CKI needs to be evaluated. PMID: 31892693 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
o FJT PMID: 31899055 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - Category: Internal Medicine Authors: Tags: Eur J Intern Med Source Type: research
More News: Cancer | Cancer & Oncology | Pain | Prostate Cancer | Urology & Nephrology